Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1027


Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.

Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, Freilino ML, Graner MW, Wikstrand CJ, Bigner DD, Gooding WE, Furnari FB, Grandis JR.

Clin Cancer Res. 2006 Sep 1;12(17):5064-73.


Insulin-like growth factor receptor as a therapeutic target in head and neck cancer.

Barnes CJ, Ohshiro K, Rayala SK, El-Naggar AK, Kumar R.

Clin Cancer Res. 2007 Jul 15;13(14):4291-9.


Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy.

Blehm KN, Spiess PE, Bondaruk JE, Dujka ME, Villares GJ, Zhao YJ, Bogler O, Aldape KD, Grossman HB, Adam L, McConkey DJ, Czerniak BA, Dinney CP, Bar-Eli M.

Clin Cancer Res. 2006 Aug 1;12(15):4671-7.


Epidermal growth factor receptor-stimulated activation of phospholipase Cgamma-1 promotes invasion of head and neck squamous cell carcinoma.

Thomas SM, Coppelli FM, Wells A, Gooding WE, Song J, Kassis J, Drenning SD, Grandis JR.

Cancer Res. 2003 Sep 1;63(17):5629-35.


Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma.

Kondo N, Tsukuda M, Ishiguro Y, Kimura M, Fujita K, Sakakibara A, Takahashi H, Toth G, Matsuda H.

Oncol Rep. 2010 Apr;23(4):957-63.


Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma.

Thomas SM, Bhola NE, Zhang Q, Contrucci SC, Wentzel AL, Freilino ML, Gooding WE, Siegfried JM, Chan DC, Grandis JR.

Cancer Res. 2006 Dec 15;66(24):11831-9.


The deletion mutant EGFRvIII significantly contributes to stress resistance typical for the tumour microenvironment.

Theys J, Jutten B, Dubois L, Rouschop KM, Chiu RK, Li Y, Paesmans K, Lambin P, Lammering G, Wouters BG.

Radiother Oncol. 2009 Sep;92(3):399-404. doi: 10.1016/j.radonc.2009.06.017. Epub 2009 Jul 16.


Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.

Uribe P, Gonzalez S.

Pathol Res Pract. 2011 Jun 15;207(6):337-42. doi: 10.1016/j.prp.2011.03.002. Epub 2011 Apr 29. Review.


Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer.

Temam S, Kawaguchi H, El-Naggar AK, Jelinek J, Tang H, Liu DD, Lang W, Issa JP, Lee JJ, Mao L.

J Clin Oncol. 2007 Jun 1;25(16):2164-70.


Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma.

Hama T, Yuza Y, Saito Y, O-uchi J, Kondo S, Okabe M, Yamada H, Kato T, Moriyama H, Kurihara S, Urashima M.

Oncologist. 2009 Sep;14(9):900-8. doi: 10.1634/theoncologist.2009-0058. Epub 2009 Sep 2. Erratum in: Oncologist. 2009 Oct;14(10):1050.


Expression of Epidermal Growth Factor Receptor variant III in laryngeal carcinoma tissues.

Yang B, Chen J, Zhang X, Cao J.

Auris Nasus Larynx. 2009 Dec;36(6):682-7. doi: 10.1016/j.anl.2009.03.002. Epub 2009 May 7.


Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter.

He Y, Zeng Q, Drenning SD, Melhem MF, Tweardy DJ, Huang L, Grandis JR.

J Natl Cancer Inst. 1998 Jul 15;90(14):1080-7. Erratum in: J Natl Cancer Inst 2002 Apr 17;94(8):633.


Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity.

Lammering G, Hewit TH, Holmes M, Valerie K, Hawkins W, Lin PS, Mikkelsen RB, Schmidt-Ullrich RK.

Clin Cancer Res. 2004 Oct 1;10(19):6732-43.


Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.

Chung CH, Ely K, McGavran L, Varella-Garcia M, Parker J, Parker N, Jarrett C, Carter J, Murphy BA, Netterville J, Burkey BB, Sinard R, Cmelak A, Levy S, Yarbrough WG, Slebos RJ, Hirsch FR.

J Clin Oncol. 2006 Sep 1;24(25):4170-6.


Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.

Luwor RB, Johns TG, Murone C, Huang HJ, Cavenee WK, Ritter G, Old LJ, Burgess AW, Scott AM.

Cancer Res. 2001 Jul 15;61(14):5355-61.


Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.

Perera RM, Narita Y, Furnari FB, Gan HK, Murone C, Ahlkvist M, Luwor RB, Burgess AW, Stockert E, Jungbluth AA, Old LJ, Cavenee WK, Scott AM, Johns TG.

Clin Cancer Res. 2005 Sep 1;11(17):6390-9.


Epidermal growth factor receptor biology in head and neck cancer.

Kalyankrishna S, Grandis JR.

J Clin Oncol. 2006 Jun 10;24(17):2666-72. Review.


Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer.

Tang CK, Gong XQ, Moscatello DK, Wong AJ, Lippman ME.

Cancer Res. 2000 Jun 1;60(11):3081-7.

Supplemental Content

Support Center